Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Paul Chaney Insider Profile
4 Followers
Paul Chaney, Director at Kiora Pharmaceuticals, holds 91.23K shares in Kiora Pharmaceuticals (Ticker: KPRX), holds 0.00 shares in Carisma Therapeutics (Ticker: CARM).
Paul Chaney has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Paul Chaney holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Feb 23, 2015 - Feb 23, 2016
Return:-54.60%
The most profitable trade made by Paul Chaney
Paul Chaney's Trading History
Kiora Pharmaceuticals
Jul 12, 2018
Director
Uninformative Buy
―
$321.58K
Carisma Therapeutics
―
Director
―
$0.00
List of latest transactions for each holding click on a transaction to see Paul Chaney's performance on stock
You May Also Like
Paul Chaney insider profile FAQ
What is the percentage of profitable transactions made by Paul Chaney?
The percentage of profitable transactions made by Paul Chaney is ―.
What is the average return per transaction made by Paul Chaney?
The average return per transaction made by Paul Chaney is ―.
What stocks does Paul Chaney hold?
Paul Chaney holds: KPRX, CARM stocks.
What was Paul Chaney’s latest transaction?
Paul Chaney latest transaction was an Uninformative Buy of ―.
What was Paul Chaney's most profitable transaction?
Paul Chaney’s most profitable transaction was an Informative Buy of KPRX stock on February 23, 2015. The return on the trade was -54.60%.
What is Paul Chaney's role in Kiora Pharmaceuticals?
Paul Chaney's role in Kiora Pharmaceuticals is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.